Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial
多拉韦林/伊斯拉曲韦（100/0.75 毫克）每日一次与比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺作为 HIV-1 初始治疗的比较：一项 3 期随机、对照、双盲、非劣效性试验的 48 周结果
期刊:Clinical Infectious Diseases
影响因子:
doi:10.1093/cid/ciaf077
Rockstroh, Jürgen K; Paredes, Roger; Cahn, Pedro; Molina, Jean-Michel; Sokhela, Simiso M; Hinestrosa, Federico; Kassim, Sheetal; Cunningham, Douglas; Ghosn, Jade; Bogner, Johannes R; Gatanaga, Hiroyuki; Asante-Appiah, Ernest; Zhang, Ying; Nwoke, Uchechukwu; Klopfer, Stephanie O; Eves, Karen; Squires, Kathleen; Correll, Todd; Fox, Michelle C; Pisculli, Mary L
